Drugs.com - Clinical Trials

Boehringer’s Zongertinib Receives Priority Review from U.S. FDA for the Treatment of HER2 (ERBB2)-Mutant Advanced Non-Small Cell Lung Cancer

Ridgefield, Conn., and Ingelheim, Germany, Feb. 19, 2025 -- Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to its new drug application for zongertinib (BI 1810631) for the treatment...

Feb 20, 2025 - 02:13
 0
Boehringer’s Zongertinib Receives Priority Review from U.S. FDA for the Treatment of HER2 (ERBB2)-Mutant Advanced Non-Small Cell Lung Cancer
Ridgefield, Conn., and Ingelheim, Germany, Feb. 19, 2025 -- Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to its new drug application for zongertinib (BI 1810631) for the treatment...
Read More

Tags:

Previous Article

Clarity Receives US FDA Fast Track Designation for the Treatment of Metastatic C...

Next Article

It’s A Ryan Reynolds Joke, Not An Issue Spotter — See Also

Related Posts

Innovent Receives Second Fast Track Designation from the U.S. FDA for IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Squamous Non-Small Cell Lung Cancer

Innovent Receives Second Fast Track Designation from th...

Feb 27, 2025  0

PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune HPV in HPV16-Positive Head and Neck Cancer

PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Tr...

Mar 9, 2025  0

Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B

Precision BioSciences Receives U.S. FDA Fast Track Desi...

Apr 16, 2025  0